To Cure Cancers
With Innovation and Speed

Committed to fight cancers with cutting-edge technologies
and innovative combination therapies, driven by a passionate team
hero-image-arrow Created with Sketch.

Our Pipeline

We are targeting multiple mechanisms to fight cancer with
single agent and combination Therapies
Training the immune
system to recognize cancers
Cancer Vaccines
Expanding and
mobilizing immune cells
Priming Agents
CTLA-4, CD137
Accelerating immune attack,
blocking immune resistance
Immune Checkpoints
PD-1, CTLA-4, CD137,
TIGIT, LAG-3, TIM-3,
etc...
Creating Inroads,
removing barriers
Tumor Microenvironment Conditioners
Bispecifics
(undisclosed)

Our Innovation Engine

We have state-of-the-art technology and manufacturing
platforms to repeatedly innovate with speed
Novel Targets

For the development of optimal therapies

GMP Manufacturing

(Berkeley, CA and Lexington, MA)

Intelligent Clinical Trials Design
Computational I-O

Integrated R&D platform for target discovery, drug development and intelligent clinical trial design

Novel Targets

For the development of optimal therapies

Publications, Presentations
& Other Stories

Scientific Conference
Presentations
Journal
Publications
Investor
Presentations

In The News

Our announcements regarding key data, regulatory
and business milestones and events
Recent
13 June 2019
Agenus to Host Annual Meeting of Stockholders
Read more >
9 May 2019
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
Read more >